$15.43
4.6643.27%
Last update: Nov 4, 6:15 PM
Lyell Immunopharma Inc
LYELNASDAQ
Lyell Immunopharma (LYEL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.92 | $-2.00 | $-2.45 | $-2.20 |
| Actual | $-1.86 | $-1.92 | $-1.10 | $-7.68 |
| Surprise | +3.12% | +4.00% | +55.1% | -249.1% |
| Revenue | ||||
| Estimate | $3290 | $4600 | $4400 | $20330 |
| Actual | $3000 | $4000 | $2000 | $6000 |
| Surprise | -8.81% | -13.0% | -54.5% | -70.5% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-1.68 | $-2.27 | $-2.43 |
| Revenue | |||
| Consensus | $2430 | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $-1.86 | $-1.92 | 3.12 % |
| Q2 | Aug 6, 2026 | $-1.92 | $-2.00 | 4.00 % |
| Q1 | May 6, 2026 | $-1.10 | $-2.45 | 55.1 % |
| Q4 | Mar 12, 2026 | $-7.68 | $-2.20 | -249.1 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $3.00K | $3.29K | -8.81 % |
| Q2 | Aug 6, 2026 | $4.00K | $4.60K | -13.0 % |
| Q1 | May 6, 2026 | $2.00K | $4.40K | -54.5 % |
| Q4 | Mar 12, 2026 | $6.00K | $20.33K | -70.5 % |
